{"gene":"ASH1L","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2000,"finding":"Human ASH1L (huASH1) protein localizes to both intranuclear speckles and intercellular tight junctions, as determined by immunostaining with multiple anti-huASH1 antibodies and double-immunofluorescence co-labeling with tight junction marker proteins in cultured cells. The protein contains a SET domain, PHD finger, four AT hooks, and a bromodomain-homology region.","method":"Immunofluorescence, double-immunofluorescence co-labeling with junctional markers, molecular cloning","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by multiple antibodies with co-labeling controls, single lab, two orthogonal methods (immunostaining + domain analysis)","pmids":["10860993"],"is_preprint":false},{"year":2007,"finding":"Mammalian ASH1L associates with the transcribed region of active genes genome-wide, and its SET domain methylates histone H3K4 in vitro. Knockdown of ASH1L reduced H3K4 trimethylation at HoxA10 in vivo. Prior methylation at H3K9 reduced ASH1L-mediated H3K4 methylation. ASH1L and MLL1 display similar chromatin distributions but are recruited independently of each other (shown in MLL null cell lines).","method":"ChIP, in vitro methyltransferase assay, siRNA knockdown with ChIP, MLL null cell lines","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro enzymatic assay plus ChIP in vivo plus genetic null cell lines; multiple orthogonal methods in one study","pmids":["17923682"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of the human ASH1L catalytic domain reveals that the substrate binding pocket is blocked by a loop from the post-SET domain (autoinhibitory loop). Mutagenesis of this loop stimulates ASH1L histone methyltransferase activity. ASH1L specifically methylates histone H3 Lys-36 in vitro.","method":"X-ray crystallography, site-directed mutagenesis, in vitro methyltransferase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis plus in vitro activity assay in single rigorous study","pmids":["21239497"],"is_preprint":false},{"year":2013,"finding":"Ash1l enhances expression of the deubiquitinase A20 (Tnfaip3) through H3K4 methylation at the Tnfaip3 promoter via its SET domain activity. A20 then facilitates deubiquitination of NF-κB signaling components NEMO and TRAF6, suppressing NF-κB and MAPK pathways and reducing IL-6 production in TLR-triggered macrophages.","method":"siRNA knockdown, ChIP, in vitro methyltransferase assay, SET domain mutant rescue, immunoprecipitation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP linking H3K4 methylation to target gene, SET domain mutant loss-of-function, epistasis via A20 downstream pathway, multiple orthogonal methods","pmids":["24012418"],"is_preprint":false},{"year":2013,"finding":"Mammalian Ash1l methylates histone H3 Lys36 (H3K36 di- and trimethylation) independently of transcriptional elongation to counteract Polycomb silencing at Hox gene loci in embryonic stem cells. Treatment with P-TEFb inhibitor DRB (which blocks elongation) showed that Ash1l-dependent H3K36 methylation and exclusion of Polycomb group proteins occur in the absence of ongoing transcription.","method":"Genetics (Ash1l knockout mouse ES cells), DRB treatment, ChIP-seq, genome-wide H3K36me analysis","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout plus pharmacological inhibition plus genome-wide ChIP-seq with multiple orthogonal approaches","pmids":["24244179"],"is_preprint":false},{"year":2015,"finding":"Two loops in the ASH1L SET domain undergo concerted conformational dynamics critical for enzymatic activity: the autoinhibitory loop (post-SET) and a second loop in the SET-I subdomain. Point mutations in either loop substantially decrease ASH1L enzymatic activity. Three C-terminal chromatin-interacting domains greatly enhance ASH1L enzymatic activity, and ASH1L requires native nucleosome substrate for robust activity.","method":"NMR, X-ray crystallography, site-directed mutagenesis, in vitro methyltransferase assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR plus X-ray crystallography plus mutagenesis plus in vitro activity assays in single study with multiple orthogonal methods","pmids":["26292256"],"is_preprint":false},{"year":2015,"finding":"In vitro kinetic characterization shows ASH1L mono- and dimethylates H3K36 using recombinant nucleosome as substrate, requires native nucleosome (not histone peptides), and is inactive toward H3K4. The post-SET basic extension is critical for ASH1L (but not SETD2) activity. A H3K36A mutation in nucleosome substrate abolishes ASH1L activity.","method":"Radioactivity-based enzyme assays, western blotting, molecular modeling, nucleosome substrate with H3K36A mutation","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutant substrate and kinetic parameters, single lab but rigorous biochemical methods","pmids":["26002201"],"is_preprint":false},{"year":2015,"finding":"Ash1l controls quiescence and self-renewal in adult hematopoietic stem cells (HSCs). Ash1l-deficient HSCs show markedly decreased quiescence, reduced Cdkn1b/1c expression, and fail to establish long-term trilineage hematopoiesis after transplantation. Ash1l also maintains expression of multiple Hox genes in hematopoietic progenitors. Combined loss of Ash1l and Mll1, but not either alone, induces overt hematopoietic failure (genetic epistasis).","method":"Conditional knockout mouse, bone marrow transplantation, cell cycle analysis, gene expression analysis, double-mutant epistasis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with specific cellular phenotype, transplantation rescue experiment, double-mutant epistasis, multiple readouts","pmids":["25866973"],"is_preprint":false},{"year":2016,"finding":"ASH1L-written H3K36me2 chromatin mark is preferentially bound in vivo by LEDGF. ASH1L facilitates recruitment of LEDGF and wild-type MLL proteins to chromatin at key leukemia target genes. The H3K36me2 demethylase KDM2A antagonizes MLL-associated leukemogenesis. ASH1L is required for MLL-dependent transcription and leukemic transformation.","method":"ChIP-seq, Co-IP, genome-wide co-localization analysis, leukemia transformation assays, KDM2A genetic/pharmacological antagonism","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal ChIP-seq showing co-localization, Co-IP for complex, functional leukemia transformation assay, multiple orthogonal methods","pmids":["27154821"],"is_preprint":false},{"year":2016,"finding":"Ash1l mediates activity-dependent transcriptional repression of neurexin-1α (nrxn1α) in neurons. Neuronal firing (50 Hz, 10 min) triggers binding of Ash1l to the nrxn1α promoter and enrichment of H3K36me2 at the promoter region. Ash1l knockout completely abolished activity-dependent repression of nrxn1α.","method":"Zinc finger protein pulldown of promoter-bound proteins, ChIP, Ash1l knockout mice, primary cortical neuron electrophysiological stimulation","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with specific molecular phenotype, ChIP for histone mark, novel protein identification at promoter; single lab","pmids":["27229316"],"is_preprint":false},{"year":2017,"finding":"ASH1L is recruited by DDB2 to UV-damaged chromatin, where it methylates H3K4 at nucleosomes containing cyclobutane pyrimidine dimers (CPDs). This H3K4me facilitates docking of XPC to nucleosomal histone octamers for handoff in global-genome NER. In ASH1L-depleted cells, XPC chromatin binding is impaired, CPD excision is suppressed, and UV hypersensitivity results. DDB2, ASH1L, and XPC transiently co-localize on H3K4-methylated nucleosomes after UV.","method":"Co-IP, ChIP, siRNA knockdown, UV survival assay, CPD excision assay, co-localization by immunofluorescence","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP, ChIP, siRNA loss-of-function with specific repair phenotype, co-localization; multiple orthogonal methods in single rigorous study","pmids":["29109511"],"is_preprint":false},{"year":2017,"finding":"Ash1l facilitates TGF-β-induced regulatory T cell (Treg) polarization by directly targeting the Smad3 promoter to increase H3K4 trimethylation and upregulate Smad3 expression. The lncRNA lnc-Smad3 competes with Ash1l by recruiting HDAC1 to silence Smad3 transcription; TGF-β-activated Smad3 suppresses lnc-Smad3, recovering promoter accessibility to Ash1l.","method":"ChIP, siRNA/shRNA knockdown, co-IP (Ash1l with Smad3 promoter), lnc-Smad3/HDAC1 interaction assay, in vitro Treg polarization","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct promoter targeting with H3K4me3, epistasis between Ash1l and lnc-Smad3/HDAC1, functional Treg polarization readout; multiple orthogonal methods","pmids":["28598443"],"is_preprint":false},{"year":2018,"finding":"Ash1L promotes myoblast fusion (MF) by activating expression of the key MF gene Cdon. Ash1L is required to counteract Polycomb repressive activity at selected myogenesis genes. Loss of Ash1L in vivo, ex vivo, and in vitro impairs myoblast fusion.","method":"RNA-seq, ChIP-seq, in vivo/ex vivo/in vitro loss-of-function (siRNA, knockout), rescue experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq for Polycomb/Ash1L occupancy, RNA-seq for target gene expression, loss-of-function in multiple systems, specific phenotypic readout","pmids":["30487570"],"is_preprint":false},{"year":2018,"finding":"Ash1l controls fate decisions of mesenchymal progenitor cells. Silencing Ash1l hampers osteogenesis and chondrogenesis while promoting adipogenesis. Overexpression of an Ash1l SET domain-containing fragment promotes osteogenic/chondrogenic differentiation. The function requires histone methyltransferase activity, as a SET-domain fragment (but not ΔN mutant lacking SET) was active. Ash1l increases H3K4me3 at promoters of osteogenic/chondrogenic transcription factors.","method":"siRNA knockdown, overexpression of SET domain fragments, ChIP (H3K4me3 at target promoters), in vitro differentiation assays, subcutaneous transplantation","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-specific rescue plus ChIP at target promoters plus in vivo transplantation; single lab","pmids":["30270478"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of ASH1L SET domain in complex with MRG15 reveals that MRG15 binds via its MRG domain to an FxLP motif in ASH1L N-terminal to the SET domain. This binding displaces the autoinhibitory (AI) loop from the post-SET domain, opening the substrate-binding pocket and activating ASH1L H3K36me2 catalytic activity.","method":"X-ray crystallography, in vitro methyltransferase assay, site-directed mutagenesis","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Strong — two independent crystal structures from two groups (PMID 30827841 and 30827843) with mechanistic validation by mutagenesis","pmids":["30827841","30827843"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of ASH1L tandem MRG15-interacting and SET domains in complex with MRG15 shows that ASH1L-MRG15 interaction principally occurs via a segment N-terminal to the SET domain. Mrg15 binding destabilizes the autoinhibitory loop in the post-SET region without direct contact, by inducing subtle structural changes in the SAM binding pocket (conformational coupling between SAM and substrate binding sites).","method":"X-ray crystallography, in vitro methyltransferase assay","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mechanistic interpretation replicated by second independent group simultaneously","pmids":["30827843"],"is_preprint":false},{"year":2021,"finding":"ASH1L knockdown in mouse prefrontal cortex (PFC) reduces H3K4me3 at promoters of ASD/epilepsy-related synaptic genes, diminishes GABAergic inhibition, enhances glutamatergic transmission, and increases PFC pyramidal neuronal excitability, causing seizures and early mortality. Chemogenetic inhibition of PFC pyramidal neurons combined with diazepam rescues synaptic imbalance and seizures.","method":"Viral shRNA knockdown in PFC, ChIP-seq (H3K4me3), whole-cell patch clamp electrophysiology, chemogenetics (DREADD), behavioral/EEG seizure monitoring","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with ChIP-seq mechanistic readout, electrophysiology, chemogenetic rescue; multiple orthogonal methods","pmids":["34782621"],"is_preprint":false},{"year":2021,"finding":"Fragment-based screening identified first-in-class small molecule inhibitors (lead compound AS-99) that bind to the autoinhibitory loop region in the ASH1L SET domain, as confirmed by crystal structures of ASH1L-inhibitor complexes. AS-99 blocks MLL leukemia cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces leukemia burden in vivo.","method":"Fragment-based screening, medicinal chemistry, X-ray crystallography of inhibitor complexes, cell proliferation/apoptosis assays, in vivo leukemia mouse models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure of inhibitor complex, structure-based design, in vitro and in vivo functional validation with multiple readouts","pmids":["33990599"],"is_preprint":false},{"year":2021,"finding":"ASH1L catalytic activity (H3K36me2) is required for promotion of MLL-AF9-induced leukemic transformation. Wild-type but not catalytic-dead ASH1L rescues leukemia maintenance in ASH1L-deleted cells. ASH1L directly binds promoters of MLL-AF9 target genes and modifies local H3K36me2 levels.","method":"Conditional knockout mouse model, retroviral rescue with WT vs. catalytic-dead ASH1L mutant, ChIP-seq, in vitro and in vivo leukemia models","journal":"Frontiers in oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic-dead mutant rescue experiment establishes enzymatic requirement, ChIP-seq for direct binding, genetic knockout with in vivo leukemia readout","pmids":["34692539"],"is_preprint":false},{"year":2022,"finding":"Ash1l haploinsufficiency causes autistic-like behaviors linked to excessive synapses due to synapse pruning deficits. Mechanistically, deletion of Ash1l in neurons leads to downregulation of EphA7 through accumulation of EZH2-mediated H3K27me3 in the EphA7 gene body. Supplying ephrin-A5 (EphA7 ligand) in Ash1l+/- mice restores synapse pruning and rescues discrimination deficits.","method":"Conditional knockout mouse, ChIP (H3K27me3 at EphA7), ephrin-A5 rescue experiment, synapse quantification, behavioral assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP showing specific epigenetic mechanism at target gene, epistasis via EphA7/ephrin-A5 rescue, specific synaptic and behavioral phenotype","pmids":["35081333"],"is_preprint":false},{"year":2022,"finding":"The ASH1L PHD finger non-selectively binds all three methylation states of H3K4 (me1, me2, me3) with comparable affinities. NMR structure of the PHD finger bound to H3K4me2 peptide shows a narrow binding groove restricting interaction with the dimethyl-ammonium moiety. The ASH1L PHD finger is identified as a native reader of methylated H3K4.","method":"NMR structure determination, peptide binding assays (ITC/NMR), site-directed mutagenesis","journal":"Frontiers in oncology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with binding affinity measurements; single lab but rigorous structural and biochemical methods","pmids":["36033518"],"is_preprint":false},{"year":2023,"finding":"The ASH1L-MRG15 complex deposits H3K4me3 genome-wide (outside active gene promoters) after UV irradiation, priming chromatin for XPC relocations. ASH1L-MRG15 also recruits the histone chaperone FACT to DNA lesions. Without ASH1L, MRG15 or FACT, XPC is misplaced and cannot deliver lesions to TFIIH for verification. Full-length MRG15 (but not MRG domain alone) enhances ASH1L activity by recruiting nucleosome substrate via MRG15 chromodomain.","method":"Co-IP, ChIP-seq, siRNA knockdown, NER activity assays, XPC relocalization imaging, in vitro methyltransferase assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, ChIP-seq, genetic knockdown with multiple pathway readouts; independent replication of ASH1L NER role (second paper from same group)","pmids":["37393406"],"is_preprint":false},{"year":2023,"finding":"Full-length MRG15 (but not the MRG domain alone) enhances ASH1L catalytic activity by recruiting ASH1L to nucleosome substrate via the MRG15 chromodomain. MRG15 binding does not alter the conformation of the ASH1L SET domain autoinhibitory loop or the SAM cofactor binding site in solution, suggesting MRG15 functions as a substrate-recruiting adapter rather than an allosteric activator.","method":"In vitro methyltransferase assay, NMR, nucleosome binding assays, MRG domain vs full-length MRG15 comparison, small molecule inhibitor potency assay","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro assay with domain dissection, NMR for conformational analysis, contrasts with prior structural models; single lab but multiple orthogonal methods","pmids":["37527654"],"is_preprint":false},{"year":2023,"finding":"METTL3 promotes ASH1L expression post-transcriptionally by enhancing ASH1L mRNA stability in a YTHDC2-dependent m6A reader mechanism. Elevated ASH1L in turn decreases IL-17 and IL-23R expression, reducing pathogenic Th17 responses.","method":"Overexpression/knockdown of METTL3, YTHDC2, and ASH1L; m6A mRNA stability assays; flow cytometry for Th17; in vivo EAU model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mRNA stability assay with YTHDC2 requirement established, functional Th17 readout, but no direct structural/enzymatic validation of ASH1L mechanism; single lab","pmids":["36753389"],"is_preprint":false},{"year":2024,"finding":"Crystal structure and functional analysis of the ASH1L C-terminal region (bromodomain, PHD finger, and BAH domain) shows: ASH1LPHD recognizes H3K4me2/3; ASH1LBD and ASH1LBAH have DNA-binding activities; the ASH1LBAH domain's DNA-binding drives association with linker DNA in nucleosomes; the PHD-BAH interface stabilizes the BAH fold merging two domains into one module; and interaction of ASH1LPHD with H3K4me3 is inhibitory to the H3K36me2 catalytic activity of ASH1L.","method":"Crystal structure, in vitro binding assays, nucleosome interaction assays, methyltransferase activity assays with domain mutants, ChIP-seq in ESCs","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus in vitro binding/activity assays plus ChIP-seq in cells; multiple orthogonal methods establishing crosstalk mechanism","pmids":["40044670"],"is_preprint":false},{"year":2024,"finding":"ASH1L mediates H3K4me3 modification at the Stac2 promoter in osteoclast progenitors, increasing Stac2 transcription. STAC2 then protects against RANKL-initiated inflammation during osteoclast formation. Conditional deletion of Ash1l in osteoclast progenitors results in osteoporosis and enhanced osteoclastogenesis in vivo.","method":"Conditional knockout mouse (osteoclast progenitor-specific), ChIP (H3K4me3 at Stac2 promoter), osteoclast differentiation assay, bone histomorphometry","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional knockout with specific phenotype, ChIP establishing direct target gene regulation; single lab","pmids":["38431690"],"is_preprint":false},{"year":2024,"finding":"Systematic perturbation of H3K36 methyltransferases demonstrates that ASH1L's H3K36me2 activity is restricted to regulatory elements of developmentally relevant genes. PBX2 is implicated as a potential ASH1L recruitment factor at these sites. ASH1L activity is positioned at the bottom of a hierarchy: NSD1 > NSD2 > NSD3 > ASH1L for H3K36me1/2 deposition.","method":"Sequential CRISPR knockouts of K36MTs in mouse mesenchymal stem cells, ChIP-seq, transcriptomics, motif analysis","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic genetic perturbation with genome-wide ChIP-seq; rigorous reductive approach establishing ASH1L-specific contribution","pmids":["39390582"],"is_preprint":false},{"year":2024,"finding":"ASH1L guards enhancer and promoter sequences against UV-induced cyclobutane pyrimidine dimer (CPD) formation at C-containing dinucleotides (but not TT dinucleotides or 6-4 photoproducts). This protective function is associated with H3K4me3 and H3K27ac histone marks that interact with ASH1L PHD and BRD motifs, respectively. Molecular dynamics simulations identified an AT hook in ASH1L that alters DNA geometry to disfavor pyrimidine dimerization.","method":"DNA damage mapping in ASH1L-proficient vs. deficient cells, molecular dynamics simulation, ChIP data correlation, mutation frequency analysis in skin cancers","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comparative DNA damage mapping in knockout cells plus MD simulation; single lab, novel mechanism (CPD prevention)","pmids":["38884271"],"is_preprint":false},{"year":2024,"finding":"ASH1L-mediated H3K4me3 modification increases CCL2 and CSF1 expression in hepatocytes and hepatic stellate cells, recruiting and polarizing M2-like pro-tumorigenic macrophages that enhance tumor proliferation and suppress CD8+ T cell activation in HCC. Conditional Ash1l deletion in hepatocytes or HSCs mitigates fibrosis and HCC development.","method":"Conditional knockout mice (Ash1lflox/flox Alb-Cre and GFAP-CreERT2), ChIP (H3K4me3 at CCL2/CSF1 promoters), single-cell RNA-seq, multicolor flow cytometry, AS-99 inhibitor treatment","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional knockouts with mechanistic ChIP data, single-cell transcriptomics, and pharmacological validation; single lab","pmids":["39377228"],"is_preprint":false},{"year":2024,"finding":"The PHD-BAH domain of ASH1L preferentially binds H3K4me2 peptide over H3K4me1 and H3K4me3 in pull-down and ITC assays. The W2603A mutation in the PHD-BAH domain disrupts interaction with H3K4me2 in vitro. Deletion of the PHD-BAH domain in cholangiocarcinoma cells increases apoptosis and reduces proliferation, with dysregulation of the PSMB family gene set.","method":"Prokaryotic fusion protein pull-down, ITC, site-directed mutagenesis, CRISPR-Cas9 domain deletion, cell proliferation/apoptosis assays","journal":"Anti-cancer agents in medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ITC binding measurements plus mutagenesis plus functional cellular readout; single lab","pmids":["39034728"],"is_preprint":false}],"current_model":"ASH1L is a Trithorax-group histone methyltransferase whose SET domain primarily catalyzes H3K36 mono- and dimethylation (and H3K4 methylation in certain contexts) on nucleosome substrates; its catalytic activity is normally autoinhibited by a post-SET loop that is relieved when MRG15 binds an FxLP motif N-terminal to the SET domain and recruits ASH1L to nucleosomes via MRG15's chromodomain. Additional C-terminal domains (PHD, BAH, bromodomain) bind H3K4me2/3 and linker DNA to stabilize chromatin association, while PHD–H3K4me3 interaction inhibits H3K36me2 catalytic activity, establishing intramolecular cross-regulation. At active genes, ASH1L-deposited H3K36me2 counteracts Polycomb silencing and is read by LEDGF to facilitate MLL complex recruitment; at DNA damage sites, DDB2-recruited ASH1L deposits H3K4me3 to enable XPC handoff and global-genome NER; in immune and neural contexts, ASH1L-mediated H3K4me3 at specific promoters activates A20/Tnfaip3, Smad3, Stac2, and synaptic genes to modulate inflammation, Treg differentiation, osteoclastogenesis, and neuronal activity."},"narrative":{"mechanistic_narrative":"ASH1L is a Trithorax-group SET-domain histone methyltransferase that deposits activating histone methylation at active genes and regulatory elements to counteract Polycomb silencing and sustain developmental gene expression programs [PMID:24244179, PMID:39390582]. Its catalytic SET domain mono- and dimethylates nucleosomal H3K36, requires intact native nucleosome substrate, and is intrinsically autoinhibited by a post-SET loop that occludes the substrate-binding pocket; mutation of this loop or a second SET-I loop relieves autoinhibition and modulates activity [PMID:21239497, PMID:26292256, PMID:26002201]. Activation in cells is achieved when MRG15 binds an FxLP motif N-terminal to the SET domain and recruits ASH1L to nucleosomes via the MRG15 chromodomain, functioning principally as a substrate-recruiting adapter [PMID:30827841, PMID:30827843, PMID:37527654]. C-terminal PHD, BAH, and bromodomain modules read H3K4 methylation and bind linker DNA to stabilize chromatin engagement, and the PHD–H3K4me3 interaction feeds back to inhibit H3K36me2 catalysis, establishing intramolecular cross-regulation [PMID:36033518, PMID:40044670]. At active and leukemia-associated loci, ASH1L-written H3K36me2 is read by LEDGF to facilitate recruitment of wild-type and fusion MLL complexes, and ASH1L catalytic activity is required for MLL-rearranged leukemic transformation, making its autoinhibitory loop a validated drug target (AS-99) [PMID:27154821, PMID:33990599, PMID:34692539]. ASH1L also deposits H3K4 methylation at specific promoters to control diverse physiological programs—enhancing the deubiquitinase A20/Tnfaip3 to restrain NF-κB-driven inflammation, Smad3 to promote Treg polarization, Stac2 in osteoclasts, and synaptic genes in neurons—and supports hematopoietic stem cell quiescence and myoblast fusion [PMID:24012418, PMID:28598443, PMID:38431690, PMID:34782621, PMID:25866973, PMID:30487570]. In genome maintenance, DDB2-recruited ASH1L, with MRG15 and FACT, methylates H3K4 at damaged nucleosomes to enable XPC handoff during global-genome nucleotide excision repair [PMID:29109511, PMID:37393406].","teleology":[{"year":2000,"claim":"Established the existence and domain architecture of human ASH1L as a multidomain chromatin protein, raising the question of where it acts in the cell.","evidence":"Immunofluorescence with multiple antibodies, co-labeling with junctional markers, and molecular cloning identifying SET, PHD, AT-hook, and bromodomain modules","pmids":["10860993"],"confidence":"Medium","gaps":["Enzymatic activity not demonstrated","Tight junction localization not mechanistically integrated with later nuclear chromatin functions"]},{"year":2007,"claim":"First showed ASH1L is a chromatin-associated methyltransferase at active genes, but assigned its SET domain to H3K4 methylation, leaving substrate specificity unsettled.","evidence":"Genome-wide ChIP, in vitro methyltransferase assay, siRNA knockdown with HoxA10 ChIP, and MLL-null cell lines","pmids":["17923682"],"confidence":"High","gaps":["H3K4 vs H3K36 specificity conflicts with later biochemistry","Recruitment mechanism to active genes undefined"]},{"year":2011,"claim":"Defined the structural basis of catalysis and reassigned the primary substrate to H3K36, revealing post-SET autoinhibition as a built-in regulatory switch.","evidence":"X-ray crystallography of the catalytic domain, mutagenesis of the autoinhibitory loop, and in vitro methyltransferase assays","pmids":["21239497"],"confidence":"High","gaps":["How autoinhibition is relieved physiologically not yet known","Nucleosome substrate requirement not addressed"]},{"year":2013,"claim":"Connected ASH1L SET activity to a Polycomb-antagonizing role in development and to direct promoter regulation of inflammatory genes, establishing functional readouts of its catalysis.","evidence":"Ash1l-knockout ES cells with DRB treatment and ChIP-seq (H3K36me2 at Hox loci); ChIP, SET-mutant rescue, and Co-IP at the Tnfaip3/A20 promoter in macrophages","pmids":["24244179","24012418"],"confidence":"High","gaps":["Recruitment factors directing ASH1L to specific loci not identified","Distinction between transcription-coupled and uncoupled methylation incomplete"]},{"year":2015,"claim":"Established that robust ASH1L activity depends on native nucleosome substrate and on coordinated SET-domain loop dynamics plus C-terminal chromatin-reader domains, refining the catalytic mechanism.","evidence":"NMR, X-ray crystallography, mutagenesis, and kinetic methyltransferase assays with recombinant nucleosomes and H3K36A substrate mutants","pmids":["26292256","26002201"],"confidence":"High","gaps":["Physiological activator of autoinhibition still unidentified","C-terminal domain contributions to chromatin targeting not structurally resolved"]},{"year":2015,"claim":"Defined ASH1L as a regulator of adult stem cell quiescence and self-renewal acting in genetic parallel with MLL1.","evidence":"Conditional knockout mice, bone marrow transplantation, cell-cycle analysis, and Ash1l/Mll1 double-mutant epistasis","pmids":["25866973"],"confidence":"High","gaps":["Direct target genes mediating quiescence beyond Hox/Cdkn1b not fully mapped","Catalytic dependence of HSC phenotype not isolated"]},{"year":2016,"claim":"Identified LEDGF as a reader of ASH1L-deposited H3K36me2 that bridges to MLL complex recruitment, defining how this mark sustains MLL-dependent leukemia.","evidence":"Reciprocal ChIP-seq co-localization, Co-IP, leukemia transformation assays, and KDM2A antagonism","pmids":["27154821"],"confidence":"High","gaps":["Whether ASH1L catalytic activity (vs scaffolding) drives transformation not resolved here","Direct ASH1L–LEDGF vs mark-mediated recruitment not distinguished"]},{"year":2016,"claim":"Extended ASH1L function to activity-dependent neuronal gene regulation, showing it can mediate transcriptional repression via promoter H3K36me2.","evidence":"Promoter pulldown, ChIP, Ash1l-knockout mice, and electrophysiological stimulation of cortical neurons","pmids":["27229316"],"confidence":"Medium","gaps":["Mechanism by which H3K36me2 represses nrxn1α not defined","Single-locus focus limits generality"]},{"year":2017,"claim":"Revealed a chromatin-priming role in DNA repair, with DDB2-recruited ASH1L methylating H3K4 to enable XPC handoff in global-genome NER.","evidence":"Co-IP, ChIP, siRNA knockdown, UV survival, CPD excision assays, and co-localization imaging","pmids":["29109511"],"confidence":"High","gaps":["H3K4 (vs H3K36) specificity at lesions contrasts with bulk biochemistry","Direct vs indirect ASH1L–XPC interplay not fully separated"]},{"year":2017,"claim":"Showed ASH1L directly activates Smad3 transcription via promoter H3K4me3 to drive Treg polarization, with a lncRNA/HDAC1 axis competing for promoter access.","evidence":"ChIP, knockdown, Co-IP at the Smad3 promoter, lnc-Smad3/HDAC1 interaction assays, and in vitro Treg polarization","pmids":["28598443"],"confidence":"High","gaps":["How TGF-β signaling spatially coordinates ASH1L recruitment unresolved","Generalizability beyond Smad3 locus untested"]},{"year":2018,"claim":"Confirmed ASH1L as a Polycomb-counteracting activator in differentiation by enabling myoblast fusion and mesenchymal lineage decisions through SET-dependent promoter activation.","evidence":"RNA-seq, ChIP-seq, multi-system loss-of-function, SET-domain fragment overexpression/rescue, and in vivo transplantation","pmids":["30487570","30270478"],"confidence":"High","gaps":["Recruitment to lineage-specific promoters not mechanistically defined","Direct vs secondary effects on differentiation factors not fully separated"]},{"year":2019,"claim":"Solved how ASH1L is physiologically activated, showing MRG15 binds an FxLP motif N-terminal to the SET domain to relieve post-SET autoinhibition.","evidence":"Independent crystal structures of ASH1L–MRG15 from two groups with methyltransferase assays and mutagenesis","pmids":["30827841","30827843"],"confidence":"High","gaps":["Whether MRG15 acts allosterically or as a substrate adapter left ambiguous","In vivo requirement of MRG15 for ASH1L targeting not established here"]},{"year":2021,"claim":"Established that ASH1L catalytic activity is required for MLL-rearranged leukemia and that its autoinhibitory loop is a druggable pocket.","evidence":"Catalytic-dead vs WT rescue in conditional knockout leukemia models with ChIP-seq; fragment-based discovery of AS-99 with inhibitor co-crystal structures and in vivo efficacy","pmids":["34692539","33990599"],"confidence":"High","gaps":["Selectivity of AS-99 against other K36 methyltransferases not detailed here","Scaffolding-independent catalytic requirement at all target genes not exhaustively mapped"]},{"year":2021,"claim":"Linked ASH1L to neurodevelopmental disease by showing its H3K4me3 deposition at synaptic genes maintains excitatory/inhibitory balance.","evidence":"Viral shRNA knockdown in prefrontal cortex, H3K4me3 ChIP-seq, patch-clamp electrophysiology, chemogenetic and pharmacological rescue","pmids":["34782621"],"confidence":"High","gaps":["Direct ASH1L promoter binding vs indirect effects not separated for all synaptic genes","Relationship to its H3K36me2 activity in neurons unclear"]},{"year":2022,"claim":"Defined the ASH1L PHD finger as a reader of methylated H3K4 and uncovered a haploinsufficiency mechanism for autism via Polycomb-mediated EphA7 silencing.","evidence":"NMR structure and binding assays of the PHD finger; conditional knockout, H3K27me3 ChIP at EphA7, and ephrin-A5 rescue with behavioral readouts","pmids":["36033518","35081333"],"confidence":"High","gaps":["How PHD H3K4me reading is coupled to catalysis not yet integrated","Direct vs indirect control of EZH2 activity at EphA7 unresolved"]},{"year":2023,"claim":"Resolved the role of MRG15 as a substrate-recruiting adapter via its chromodomain and extended the ASH1L–MRG15 module to FACT recruitment in NER.","evidence":"Co-IP, ChIP-seq, NER assays, XPC imaging, and in vitro methyltransferase assays comparing full-length MRG15 vs MRG domain alone","pmids":["37393406","37527654"],"confidence":"High","gaps":["Reconciliation of adapter vs allosteric models across studies incomplete","In vivo stoichiometry of the ASH1L–MRG15–FACT module unknown"]},{"year":2023,"claim":"Placed ASH1L downstream of m6A regulation, showing METTL3/YTHDC2 stabilize ASH1L mRNA to dampen pathogenic Th17 responses.","evidence":"Overexpression/knockdown of METTL3, YTHDC2 and ASH1L, m6A mRNA stability assays, Th17 flow cytometry, and an in vivo EAU model","pmids":["36753389"],"confidence":"Medium","gaps":["No structural/enzymatic validation of ASH1L action on IL-17/IL-23R","Direct ASH1L target promoters in Th17 not identified"]},{"year":2024,"claim":"Defined the integrated C-terminal reader module (PHD-BAH-bromodomain) and its DNA/H3K4me binding, revealing PHD–H3K4me3-dependent inhibition of catalysis as intramolecular cross-regulation.","evidence":"Crystal structure, in vitro binding and nucleosome assays, domain-mutant methyltransferase assays, ITC, and ChIP-seq in ESCs and cancer cells","pmids":["40044670","39034728"],"confidence":"High","gaps":["How reader-mediated feedback is regulated in vivo unknown","Conflicting H3K4 methyl-state preferences across PHD vs PHD-BAH constructs"]},{"year":2024,"claim":"Quantified ASH1L's restricted, hierarchical contribution to H3K36me2 at developmental regulatory elements and nominated PBX2 as a recruitment factor.","evidence":"Sequential CRISPR knockouts of K36 methyltransferases in mesenchymal stem cells with ChIP-seq, transcriptomics, and motif analysis","pmids":["39390582"],"confidence":"High","gaps":["Direct PBX2–ASH1L interaction not biochemically validated","Mechanism setting the NSD>ASH1L hierarchy unexplained"]},{"year":2024,"claim":"Extended ASH1L H3K4me3 promoter activation to additional disease-relevant programs and uncovered a non-catalytic DNA-protective function against UV damage.","evidence":"Osteoclast- and hepatocyte/HSC-specific conditional knockouts with ChIP at Stac2/CCL2/CSF1 promoters and AS-99 treatment; DNA damage mapping plus molecular dynamics of an AT hook in ASH1L-deficient cells","pmids":["38431690","39377228","38884271"],"confidence":"Medium","gaps":["AT-hook-mediated CPD prevention is a single-lab novel mechanism awaiting independent confirmation","Catalytic vs structural contributions to the protective role not separated"]},{"year":null,"claim":"How ASH1L's locus-specific recruitment, the catalytic switch between H3K36me2 and context-dependent H3K4 methylation, and reader-mediated feedback are integrated into a unified targeting logic in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model reconciling H3K36me2 vs H3K4 methylation outputs across contexts","Sequence-specific recruitment factors largely unvalidated biochemically","In vivo interplay of autoinhibition, MRG15 activation, and PHD feedback not measured"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[2,6,14]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,6,24]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[20,24,29]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[24,27]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,4,11]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[1,4,24]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,24,26]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,3,11]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[10,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,12,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,11,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,17,18,28]}],"complexes":["ASH1L-MRG15 complex"],"partners":["MRG15","LEDGF","DDB2","XPC","FACT"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NR48","full_name":"Histone-lysine N-methyltransferase ASH1L","aliases":["ASH1-like protein","huASH1","Absent small and homeotic disks protein 1 homolog","Lysine N-methyltransferase 2H"],"length_aa":2969,"mass_kda":332.8,"function":"Histone methyltransferase specifically trimethylating 'Lys-36' of histone H3 forming H3K36me3 (PubMed:21239497). Also monomethylates 'Lys-9' of histone H3 (H3K9me1) in vitro (By similarity). The physiological significance of the H3K9me1 activity is unclear (By similarity)","subcellular_location":"Nucleus; Cell junction, tight junction; Chromosome","url":"https://www.uniprot.org/uniprotkb/Q9NR48/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ASH1L","classification":"Not Classified","n_dependent_lines":85,"n_total_lines":1208,"dependency_fraction":0.07036423841059603},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ASH1L","total_profiled":1310},"omim":[{"mim_id":"617796","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 52; MRD52","url":"https://www.omim.org/entry/617796"},{"mim_id":"614865","title":"D4Z4 BINDING ELEMENT TRANSCRIPT, NONCODING; DBET","url":"https://www.omim.org/entry/614865"},{"mim_id":"613208","title":"XPC COMPLEX SUBUNIT, DNA DAMAGE RECOGNITION AND REPAIR FACTOR; XPC","url":"https://www.omim.org/entry/613208"},{"mim_id":"607999","title":"ASH1-LIKE HISTONE LYSINE METHYLTRANSFERASE; ASH1L","url":"https://www.omim.org/entry/607999"},{"mim_id":"607860","title":"YY1 ASSOCIATED PROTEIN 1; YY1AP1","url":"https://www.omim.org/entry/607860"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Nuclear bodies","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ASH1L"},"hgnc":{"alias_symbol":["huASH1","ASH1","ASH1L1","KMT2H"],"prev_symbol":[]},"alphafold":{"accession":"Q9NR48","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NR48","model_url":"","pae_url":"","plddt_mean":null},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ASH1L","jax_strain_url":"https://www.jax.org/strain/search?query=ASH1L"},"sequence":{"accession":"Q9NR48","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NR48.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NR48/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NR48"}},"corpus_meta":[{"pmid":"17923682","id":"PMC_17923682","title":"Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17923682","citation_count":177,"is_preprint":false},{"pmid":"24012418","id":"PMC_24012418","title":"Histone methyltransferase Ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme A20.","date":"2013","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24012418","citation_count":137,"is_preprint":false},{"pmid":"27154821","id":"PMC_27154821","title":"ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.","date":"2016","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27154821","citation_count":133,"is_preprint":false},{"pmid":"21239497","id":"PMC_21239497","title":"Crystal structure of the human histone methyltransferase ASH1L catalytic domain and its implications for the regulatory mechanism.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21239497","citation_count":112,"is_preprint":false},{"pmid":"10860993","id":"PMC_10860993","title":"huASH1 protein, a putative transcription factor encoded by a human homologue of the Drosophila ash1 gene, localizes to both nuclei and cell-cell tight junctions.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10860993","citation_count":92,"is_preprint":false},{"pmid":"24244179","id":"PMC_24244179","title":"Ash1l methylates Lys36 of histone H3 independently of transcriptional elongation to counteract polycomb silencing.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24244179","citation_count":76,"is_preprint":false},{"pmid":"28598443","id":"PMC_28598443","title":"Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28598443","citation_count":62,"is_preprint":false},{"pmid":"30270478","id":"PMC_30270478","title":"Epigenetic Control of Mesenchymal Stem Cell Fate Decision via Histone Methyltransferase Ash1l.","date":"2018","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/30270478","citation_count":60,"is_preprint":false},{"pmid":"25866973","id":"PMC_25866973","title":"Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25866973","citation_count":58,"is_preprint":false},{"pmid":"34782621","id":"PMC_34782621","title":"Deficiency of autism risk factor ASH1L in prefrontal cortex induces epigenetic aberrations and seizures.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34782621","citation_count":54,"is_preprint":false},{"pmid":"31673123","id":"PMC_31673123","title":"Mutations in ASH1L confer susceptibility to Tourette syndrome.","date":"2019","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/31673123","citation_count":53,"is_preprint":false},{"pmid":"25238203","id":"PMC_25238203","title":"miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25238203","citation_count":53,"is_preprint":false},{"pmid":"26002201","id":"PMC_26002201","title":"Kinetic characterization of human histone H3 lysine 36 methyltransferases, ASH1L and SETD2.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26002201","citation_count":42,"is_preprint":false},{"pmid":"35081333","id":"PMC_35081333","title":"ASH1L haploinsufficiency results in autistic-like phenotypes in mice and links Eph receptor gene to autism spectrum disorder.","date":"2022","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/35081333","citation_count":41,"is_preprint":false},{"pmid":"33990599","id":"PMC_33990599","title":"Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33990599","citation_count":38,"is_preprint":false},{"pmid":"32398261","id":"PMC_32398261","title":"Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32398261","citation_count":37,"is_preprint":false},{"pmid":"30827843","id":"PMC_30827843","title":"Structural Insights into Stimulation of Ash1L's H3K36 Methyltransferase Activity through Mrg15 Binding.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30827843","citation_count":32,"is_preprint":false},{"pmid":"28394464","id":"PMC_28394464","title":"Novel MCA/ID syndrome with ASH1L mutation.","date":"2017","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/28394464","citation_count":31,"is_preprint":false},{"pmid":"27229316","id":"PMC_27229316","title":"Histone methyltransferase Ash1L mediates activity-dependent repression of neurexin-1α.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27229316","citation_count":29,"is_preprint":false},{"pmid":"34145365","id":"PMC_34145365","title":"Loss of histone methyltransferase ASH1L in the developing mouse brain causes autistic-like behaviors.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34145365","citation_count":28,"is_preprint":false},{"pmid":"28374742","id":"PMC_28374742","title":"The Histone Methyltransferase Ash1l is Required for Epidermal Homeostasis in Mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28374742","citation_count":27,"is_preprint":false},{"pmid":"26292256","id":"PMC_26292256","title":"Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26292256","citation_count":27,"is_preprint":false},{"pmid":"26549848","id":"PMC_26549848","title":"Reprogramming of Polycomb-Mediated Gene Silencing in Embryonic Stem Cells by the miR-290 Family and the Methyltransferase Ash1l.","date":"2015","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26549848","citation_count":27,"is_preprint":false},{"pmid":"36753389","id":"PMC_36753389","title":"METTL3 inhibits autoreactive Th17 cell responses in experimental autoimmune uveitis via stabilizing ASH1L mRNA.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/36753389","citation_count":25,"is_preprint":false},{"pmid":"29109511","id":"PMC_29109511","title":"ASH1L histone methyltransferase regulates the handoff between damage recognition factors in global-genome nucleotide excision repair.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29109511","citation_count":25,"is_preprint":false},{"pmid":"36582030","id":"PMC_36582030","title":"Exosomes from hypoxia-pretreated adipose-derived stem cells attenuate ultraviolet light-induced skin injury via delivery of circ-Ash1l.","date":"2023","source":"Photodermatology, photoimmunology & photomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/36582030","citation_count":23,"is_preprint":false},{"pmid":"30827841","id":"PMC_30827841","title":"Structural Basis of MRG15-Mediated Activation of the ASH1L Histone Methyltransferase by Releasing an Autoinhibitory Loop.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30827841","citation_count":23,"is_preprint":false},{"pmid":"39377228","id":"PMC_39377228","title":"ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39377228","citation_count":22,"is_preprint":false},{"pmid":"37805663","id":"PMC_37805663","title":"The ASH1L-AS1-ASH1L axis controls NME1-mediated activation of the RAS signaling in gastric cancer.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/37805663","citation_count":22,"is_preprint":false},{"pmid":"33258273","id":"PMC_33258273","title":"Role of Ash1l in Tourette syndrome and other neurodevelopmental disorders.","date":"2020","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/33258273","citation_count":19,"is_preprint":false},{"pmid":"30487570","id":"PMC_30487570","title":"The Trithorax protein Ash1L promotes myoblast fusion by activating Cdon expression.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30487570","citation_count":18,"is_preprint":false},{"pmid":"39390582","id":"PMC_39390582","title":"Systematic perturbations of SETD2, NSD1, NSD2, NSD3, and ASH1L reveal their distinct contributions to H3K36 methylation.","date":"2024","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/39390582","citation_count":15,"is_preprint":false},{"pmid":"34692539","id":"PMC_34692539","title":"Histone H3K36me2-Specific Methyltransferase ASH1L Promotes MLL-AF9-Induced Leukemogenesis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34692539","citation_count":14,"is_preprint":false},{"pmid":"37296904","id":"PMC_37296904","title":"Novel NUP98::ASH1L Gene Fusion in Acute Myeloid Leukemia Detected by Optical Genome Mapping.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37296904","citation_count":14,"is_preprint":false},{"pmid":"34509565","id":"PMC_34509565","title":"Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/34509565","citation_count":14,"is_preprint":false},{"pmid":"28041684","id":"PMC_28041684","title":"ASH1L Suppresses Matrix Metalloproteinase through Mitogen-activated Protein Kinase Signaling Pathway in Pulpitis.","date":"2016","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/28041684","citation_count":13,"is_preprint":false},{"pmid":"34373061","id":"PMC_34373061","title":"ASH1L mutation caused seizures and intellectual disability in twin sisters.","date":"2021","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/34373061","citation_count":13,"is_preprint":false},{"pmid":"37393406","id":"PMC_37393406","title":"ASH1L-MRG15 methyltransferase deposits H3K4me3 and FACT for damage verification in nucleotide excision repair.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37393406","citation_count":13,"is_preprint":false},{"pmid":"36033518","id":"PMC_36033518","title":"Structural insight into ASH1L PHD finger recognizing methylated histone H3K4 and promoting cell growth in prostate cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36033518","citation_count":13,"is_preprint":false},{"pmid":"32518592","id":"PMC_32518592","title":"A chromosome 1q22 microdeletion including ASH1L is associated with intellectual disability in a Chinese family.","date":"2020","source":"Molecular cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/32518592","citation_count":10,"is_preprint":false},{"pmid":"38674358","id":"PMC_38674358","title":"Expansion of the Genotypic and Phenotypic Spectrum of ASH1L-Related Syndromic Neurodevelopmental Disorder.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38674358","citation_count":9,"is_preprint":false},{"pmid":"33296745","id":"PMC_33296745","title":"Knockdown of ASH1L methyltransferase induced apoptosis inhibiting proliferation and H3K36 methylation in bovine cumulus cells.","date":"2020","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/33296745","citation_count":9,"is_preprint":false},{"pmid":"38431690","id":"PMC_38431690","title":"The histone methyltransferase ASH1L protects against bone loss by inhibiting osteoclastogenesis.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/38431690","citation_count":8,"is_preprint":false},{"pmid":"37766518","id":"PMC_37766518","title":"Ash1L ameliorates psoriasis via limiting neuronal activity-dependent release of miR-let-7b.","date":"2023","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37766518","citation_count":8,"is_preprint":false},{"pmid":"31067442","id":"PMC_31067442","title":"Unleashing the Power of ASH1L Methyltransferase.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31067442","citation_count":8,"is_preprint":false},{"pmid":"35196069","id":"PMC_35196069","title":"The methyltransferase enzymes KMT2D, SETD1B, and ASH1L are key mediators of both metabolic and epigenetic changes during cellular senescence.","date":"2022","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/35196069","citation_count":8,"is_preprint":false},{"pmid":"27434206","id":"PMC_27434206","title":"ASH1L (a histone methyltransferase protein) is a novel candidate globin gene regulator revealed by genetic study of an English family with beta-thalassaemia unlinked to the beta-globin locus.","date":"2016","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/27434206","citation_count":8,"is_preprint":false},{"pmid":"40646641","id":"PMC_40646641","title":"Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma.","date":"2025","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/40646641","citation_count":7,"is_preprint":false},{"pmid":"36094439","id":"PMC_36094439","title":"ASH1L contributes to oocyte apoptosis by regulating DNA damage.","date":"2022","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36094439","citation_count":6,"is_preprint":false},{"pmid":"38943682","id":"PMC_38943682","title":"Ash1l loss-of-function results in structural birth defects and altered cortical development.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38943682","citation_count":5,"is_preprint":false},{"pmid":"37527654","id":"PMC_37527654","title":"MRG15 activates histone methyltransferase activity of ASH1L by recruiting it to the nucleosomes.","date":"2023","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/37527654","citation_count":5,"is_preprint":false},{"pmid":"37952156","id":"PMC_37952156","title":"Hypoxia-sensitive cells trigger NK cell activation via the KLF4-ASH1L-ICAM-1 axis, contributing to impairment in the rat epididymis.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37952156","citation_count":5,"is_preprint":false},{"pmid":"35449559","id":"PMC_35449559","title":"Neural Hyperactivity Is a Core Pathophysiological Change Induced by Deletion of a High Autism Risk Gene Ash1L in the Mouse Brain.","date":"2022","source":"Frontiers in behavioral neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35449559","citation_count":4,"is_preprint":false},{"pmid":"40044670","id":"PMC_40044670","title":"Structure-function relationship of ASH1L and histone H3K36 and H3K4 methylation.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40044670","citation_count":3,"is_preprint":false},{"pmid":"39902220","id":"PMC_39902220","title":"Novel heterozygous ASH1L nonsense variant involved in mild intellectual disability.","date":"2025","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39902220","citation_count":3,"is_preprint":false},{"pmid":"39748122","id":"PMC_39748122","title":"Has_circ_ASH1L acts as a sponge for miR-1254 to promote the malignant progression of cervical cancer by targeting CD36.","date":"2025","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39748122","citation_count":3,"is_preprint":false},{"pmid":"37905045","id":"PMC_37905045","title":"Systematic perturbations of SETD2, NSD1, NSD2, NSD3 and ASH1L reveals their distinct contributions to H3K36 methylation.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37905045","citation_count":3,"is_preprint":false},{"pmid":"38884271","id":"PMC_38884271","title":"ASH1L guards cis-regulatory elements against cyclobutane pyrimidine dimer induction.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38884271","citation_count":2,"is_preprint":false},{"pmid":"39680643","id":"PMC_39680643","title":"Structure-Based Development of Novel Spiro-Piperidine ASH1L Inhibitors.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39680643","citation_count":2,"is_preprint":false},{"pmid":"39777247","id":"PMC_39777247","title":"Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression.","date":"2025","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/39777247","citation_count":2,"is_preprint":false},{"pmid":"41017397","id":"PMC_41017397","title":"CircSHOC2 regulates steroid hormone synthesis in ovarian granulosa cells through the mir-130b-5p/ASH1L pathway.","date":"2025","source":"Zoological research","url":"https://pubmed.ncbi.nlm.nih.gov/41017397","citation_count":2,"is_preprint":false},{"pmid":"38634863","id":"PMC_38634863","title":"Abnormal H3K4 enzyme catalytic activity and neuronal morphology caused by ASH1L mutations in individuals with Tourette syndrome.","date":"2024","source":"European child & adolescent psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38634863","citation_count":1,"is_preprint":false},{"pmid":"39034728","id":"PMC_39034728","title":"PHD-BAH Domain in ASH1L Could Recognize H3K4 Methylation and Regulate the Malignant Behavior of Cholangiocarcinoma.","date":"2024","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39034728","citation_count":1,"is_preprint":false},{"pmid":"39766886","id":"PMC_39766886","title":"Chemogenetic Inhibition of Prefrontal Cortex Ameliorates Autism-Like Social Deficits and Absence-Like Seizures in a Gene-Trap Ash1l Haploinsufficiency Mouse Model.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/39766886","citation_count":1,"is_preprint":false},{"pmid":"38174187","id":"PMC_38174187","title":"A Saudi Girl With Co-occurring CHD1 (Pilarowski-Bjornsson Syndrome) and ASH1L Gene Variants.","date":"2023","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/38174187","citation_count":1,"is_preprint":false},{"pmid":"39655631","id":"PMC_39655631","title":"Gonadal Mosaicism for an ASH1L Intragenic Deletion Makes a Bridge Between MRD52 and 1q22 Microdeletion.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/39655631","citation_count":1,"is_preprint":false},{"pmid":"41327308","id":"PMC_41327308","title":"Revealing the impact of partial gene duplications in ASH1L: integration of optical genome mapping and RNA sequencing.","date":"2025","source":"Molecular cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/41327308","citation_count":0,"is_preprint":false},{"pmid":"39677608","id":"PMC_39677608","title":"Dynamic Regulation OF The Chromatin Environment By Ash1L Modulates Human Neuronal Structure And Function.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39677608","citation_count":0,"is_preprint":false},{"pmid":"40504347","id":"PMC_40504347","title":"Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40504347","citation_count":0,"is_preprint":false},{"pmid":"41283842","id":"PMC_41283842","title":"[Evolution of DEE-SWAS into photosensitive epilepsy in a patient with an ASH1L gene mutation].","date":"2025","source":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","url":"https://pubmed.ncbi.nlm.nih.gov/41283842","citation_count":0,"is_preprint":false},{"pmid":"42083345","id":"PMC_42083345","title":"The Emerging Role of Histone Methyltransferase ASH1L in Tumor Development.","date":"2026","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/42083345","citation_count":0,"is_preprint":false},{"pmid":"42220427","id":"PMC_42220427","title":"CDK4 Mediates Cisplatin Resistance in Renal Cell Carcinoma (RCC) Cells by Regulating the ASH1L-CTR1 Axis.","date":"2026","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/42220427","citation_count":0,"is_preprint":false},{"pmid":"41291913","id":"PMC_41291913","title":"A novel de novo missense variant in ASH1L associated with mild autism spectrum disorder and an uneven cognitive profile: a case report.","date":"2025","source":"Journal of medical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41291913","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.28.656415","title":"Sequential transcriptional gates in the thalamo-cortical circuit coordinate memory stabilization","date":"2025-05-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.28.656415","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.21.639570","title":"Mutations in ASH1L cause a neurodevelopmental disorder with sex differences in epilepsy and autism","date":"2025-02-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.21.639570","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.15.638273","title":"Structural patterns and transcriptional effects of integrated Epstein-Barr virus revealed by long-read sequencing and RNA-sequencing in Nasopharyngeal Carcinoma","date":"2025-02-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.15.638273","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.13.617729","title":"Assembloid model to study loop circuits of the human nervous system","date":"2024-10-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.13.617729","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.10.607446","title":"H3K36 Methylation - a Guardian of Epigenome Integrity","date":"2024-08-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.10.607446","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38456,"output_tokens":8194,"usd":0.119139,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17852,"output_tokens":6454,"usd":0.125305,"stage2_stop_reason":"end_turn"},"total_usd":0.244444,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Human ASH1L (huASH1) protein localizes to both intranuclear speckles and intercellular tight junctions, as determined by immunostaining with multiple anti-huASH1 antibodies and double-immunofluorescence co-labeling with tight junction marker proteins in cultured cells. The protein contains a SET domain, PHD finger, four AT hooks, and a bromodomain-homology region.\",\n      \"method\": \"Immunofluorescence, double-immunofluorescence co-labeling with junctional markers, molecular cloning\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by multiple antibodies with co-labeling controls, single lab, two orthogonal methods (immunostaining + domain analysis)\",\n      \"pmids\": [\"10860993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mammalian ASH1L associates with the transcribed region of active genes genome-wide, and its SET domain methylates histone H3K4 in vitro. Knockdown of ASH1L reduced H3K4 trimethylation at HoxA10 in vivo. Prior methylation at H3K9 reduced ASH1L-mediated H3K4 methylation. ASH1L and MLL1 display similar chromatin distributions but are recruited independently of each other (shown in MLL null cell lines).\",\n      \"method\": \"ChIP, in vitro methyltransferase assay, siRNA knockdown with ChIP, MLL null cell lines\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro enzymatic assay plus ChIP in vivo plus genetic null cell lines; multiple orthogonal methods in one study\",\n      \"pmids\": [\"17923682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of the human ASH1L catalytic domain reveals that the substrate binding pocket is blocked by a loop from the post-SET domain (autoinhibitory loop). Mutagenesis of this loop stimulates ASH1L histone methyltransferase activity. ASH1L specifically methylates histone H3 Lys-36 in vitro.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, in vitro methyltransferase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis plus in vitro activity assay in single rigorous study\",\n      \"pmids\": [\"21239497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ash1l enhances expression of the deubiquitinase A20 (Tnfaip3) through H3K4 methylation at the Tnfaip3 promoter via its SET domain activity. A20 then facilitates deubiquitination of NF-κB signaling components NEMO and TRAF6, suppressing NF-κB and MAPK pathways and reducing IL-6 production in TLR-triggered macrophages.\",\n      \"method\": \"siRNA knockdown, ChIP, in vitro methyltransferase assay, SET domain mutant rescue, immunoprecipitation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP linking H3K4 methylation to target gene, SET domain mutant loss-of-function, epistasis via A20 downstream pathway, multiple orthogonal methods\",\n      \"pmids\": [\"24012418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Mammalian Ash1l methylates histone H3 Lys36 (H3K36 di- and trimethylation) independently of transcriptional elongation to counteract Polycomb silencing at Hox gene loci in embryonic stem cells. Treatment with P-TEFb inhibitor DRB (which blocks elongation) showed that Ash1l-dependent H3K36 methylation and exclusion of Polycomb group proteins occur in the absence of ongoing transcription.\",\n      \"method\": \"Genetics (Ash1l knockout mouse ES cells), DRB treatment, ChIP-seq, genome-wide H3K36me analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout plus pharmacological inhibition plus genome-wide ChIP-seq with multiple orthogonal approaches\",\n      \"pmids\": [\"24244179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Two loops in the ASH1L SET domain undergo concerted conformational dynamics critical for enzymatic activity: the autoinhibitory loop (post-SET) and a second loop in the SET-I subdomain. Point mutations in either loop substantially decrease ASH1L enzymatic activity. Three C-terminal chromatin-interacting domains greatly enhance ASH1L enzymatic activity, and ASH1L requires native nucleosome substrate for robust activity.\",\n      \"method\": \"NMR, X-ray crystallography, site-directed mutagenesis, in vitro methyltransferase assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR plus X-ray crystallography plus mutagenesis plus in vitro activity assays in single study with multiple orthogonal methods\",\n      \"pmids\": [\"26292256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In vitro kinetic characterization shows ASH1L mono- and dimethylates H3K36 using recombinant nucleosome as substrate, requires native nucleosome (not histone peptides), and is inactive toward H3K4. The post-SET basic extension is critical for ASH1L (but not SETD2) activity. A H3K36A mutation in nucleosome substrate abolishes ASH1L activity.\",\n      \"method\": \"Radioactivity-based enzyme assays, western blotting, molecular modeling, nucleosome substrate with H3K36A mutation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutant substrate and kinetic parameters, single lab but rigorous biochemical methods\",\n      \"pmids\": [\"26002201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ash1l controls quiescence and self-renewal in adult hematopoietic stem cells (HSCs). Ash1l-deficient HSCs show markedly decreased quiescence, reduced Cdkn1b/1c expression, and fail to establish long-term trilineage hematopoiesis after transplantation. Ash1l also maintains expression of multiple Hox genes in hematopoietic progenitors. Combined loss of Ash1l and Mll1, but not either alone, induces overt hematopoietic failure (genetic epistasis).\",\n      \"method\": \"Conditional knockout mouse, bone marrow transplantation, cell cycle analysis, gene expression analysis, double-mutant epistasis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with specific cellular phenotype, transplantation rescue experiment, double-mutant epistasis, multiple readouts\",\n      \"pmids\": [\"25866973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ASH1L-written H3K36me2 chromatin mark is preferentially bound in vivo by LEDGF. ASH1L facilitates recruitment of LEDGF and wild-type MLL proteins to chromatin at key leukemia target genes. The H3K36me2 demethylase KDM2A antagonizes MLL-associated leukemogenesis. ASH1L is required for MLL-dependent transcription and leukemic transformation.\",\n      \"method\": \"ChIP-seq, Co-IP, genome-wide co-localization analysis, leukemia transformation assays, KDM2A genetic/pharmacological antagonism\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal ChIP-seq showing co-localization, Co-IP for complex, functional leukemia transformation assay, multiple orthogonal methods\",\n      \"pmids\": [\"27154821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Ash1l mediates activity-dependent transcriptional repression of neurexin-1α (nrxn1α) in neurons. Neuronal firing (50 Hz, 10 min) triggers binding of Ash1l to the nrxn1α promoter and enrichment of H3K36me2 at the promoter region. Ash1l knockout completely abolished activity-dependent repression of nrxn1α.\",\n      \"method\": \"Zinc finger protein pulldown of promoter-bound proteins, ChIP, Ash1l knockout mice, primary cortical neuron electrophysiological stimulation\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with specific molecular phenotype, ChIP for histone mark, novel protein identification at promoter; single lab\",\n      \"pmids\": [\"27229316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ASH1L is recruited by DDB2 to UV-damaged chromatin, where it methylates H3K4 at nucleosomes containing cyclobutane pyrimidine dimers (CPDs). This H3K4me facilitates docking of XPC to nucleosomal histone octamers for handoff in global-genome NER. In ASH1L-depleted cells, XPC chromatin binding is impaired, CPD excision is suppressed, and UV hypersensitivity results. DDB2, ASH1L, and XPC transiently co-localize on H3K4-methylated nucleosomes after UV.\",\n      \"method\": \"Co-IP, ChIP, siRNA knockdown, UV survival assay, CPD excision assay, co-localization by immunofluorescence\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP, ChIP, siRNA loss-of-function with specific repair phenotype, co-localization; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"29109511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Ash1l facilitates TGF-β-induced regulatory T cell (Treg) polarization by directly targeting the Smad3 promoter to increase H3K4 trimethylation and upregulate Smad3 expression. The lncRNA lnc-Smad3 competes with Ash1l by recruiting HDAC1 to silence Smad3 transcription; TGF-β-activated Smad3 suppresses lnc-Smad3, recovering promoter accessibility to Ash1l.\",\n      \"method\": \"ChIP, siRNA/shRNA knockdown, co-IP (Ash1l with Smad3 promoter), lnc-Smad3/HDAC1 interaction assay, in vitro Treg polarization\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct promoter targeting with H3K4me3, epistasis between Ash1l and lnc-Smad3/HDAC1, functional Treg polarization readout; multiple orthogonal methods\",\n      \"pmids\": [\"28598443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ash1L promotes myoblast fusion (MF) by activating expression of the key MF gene Cdon. Ash1L is required to counteract Polycomb repressive activity at selected myogenesis genes. Loss of Ash1L in vivo, ex vivo, and in vitro impairs myoblast fusion.\",\n      \"method\": \"RNA-seq, ChIP-seq, in vivo/ex vivo/in vitro loss-of-function (siRNA, knockout), rescue experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq for Polycomb/Ash1L occupancy, RNA-seq for target gene expression, loss-of-function in multiple systems, specific phenotypic readout\",\n      \"pmids\": [\"30487570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ash1l controls fate decisions of mesenchymal progenitor cells. Silencing Ash1l hampers osteogenesis and chondrogenesis while promoting adipogenesis. Overexpression of an Ash1l SET domain-containing fragment promotes osteogenic/chondrogenic differentiation. The function requires histone methyltransferase activity, as a SET-domain fragment (but not ΔN mutant lacking SET) was active. Ash1l increases H3K4me3 at promoters of osteogenic/chondrogenic transcription factors.\",\n      \"method\": \"siRNA knockdown, overexpression of SET domain fragments, ChIP (H3K4me3 at target promoters), in vitro differentiation assays, subcutaneous transplantation\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-specific rescue plus ChIP at target promoters plus in vivo transplantation; single lab\",\n      \"pmids\": [\"30270478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of ASH1L SET domain in complex with MRG15 reveals that MRG15 binds via its MRG domain to an FxLP motif in ASH1L N-terminal to the SET domain. This binding displaces the autoinhibitory (AI) loop from the post-SET domain, opening the substrate-binding pocket and activating ASH1L H3K36me2 catalytic activity.\",\n      \"method\": \"X-ray crystallography, in vitro methyltransferase assay, site-directed mutagenesis\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two independent crystal structures from two groups (PMID 30827841 and 30827843) with mechanistic validation by mutagenesis\",\n      \"pmids\": [\"30827841\", \"30827843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of ASH1L tandem MRG15-interacting and SET domains in complex with MRG15 shows that ASH1L-MRG15 interaction principally occurs via a segment N-terminal to the SET domain. Mrg15 binding destabilizes the autoinhibitory loop in the post-SET region without direct contact, by inducing subtle structural changes in the SAM binding pocket (conformational coupling between SAM and substrate binding sites).\",\n      \"method\": \"X-ray crystallography, in vitro methyltransferase assay\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mechanistic interpretation replicated by second independent group simultaneously\",\n      \"pmids\": [\"30827843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ASH1L knockdown in mouse prefrontal cortex (PFC) reduces H3K4me3 at promoters of ASD/epilepsy-related synaptic genes, diminishes GABAergic inhibition, enhances glutamatergic transmission, and increases PFC pyramidal neuronal excitability, causing seizures and early mortality. Chemogenetic inhibition of PFC pyramidal neurons combined with diazepam rescues synaptic imbalance and seizures.\",\n      \"method\": \"Viral shRNA knockdown in PFC, ChIP-seq (H3K4me3), whole-cell patch clamp electrophysiology, chemogenetics (DREADD), behavioral/EEG seizure monitoring\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with ChIP-seq mechanistic readout, electrophysiology, chemogenetic rescue; multiple orthogonal methods\",\n      \"pmids\": [\"34782621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fragment-based screening identified first-in-class small molecule inhibitors (lead compound AS-99) that bind to the autoinhibitory loop region in the ASH1L SET domain, as confirmed by crystal structures of ASH1L-inhibitor complexes. AS-99 blocks MLL leukemia cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces leukemia burden in vivo.\",\n      \"method\": \"Fragment-based screening, medicinal chemistry, X-ray crystallography of inhibitor complexes, cell proliferation/apoptosis assays, in vivo leukemia mouse models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure of inhibitor complex, structure-based design, in vitro and in vivo functional validation with multiple readouts\",\n      \"pmids\": [\"33990599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ASH1L catalytic activity (H3K36me2) is required for promotion of MLL-AF9-induced leukemic transformation. Wild-type but not catalytic-dead ASH1L rescues leukemia maintenance in ASH1L-deleted cells. ASH1L directly binds promoters of MLL-AF9 target genes and modifies local H3K36me2 levels.\",\n      \"method\": \"Conditional knockout mouse model, retroviral rescue with WT vs. catalytic-dead ASH1L mutant, ChIP-seq, in vitro and in vivo leukemia models\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic-dead mutant rescue experiment establishes enzymatic requirement, ChIP-seq for direct binding, genetic knockout with in vivo leukemia readout\",\n      \"pmids\": [\"34692539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Ash1l haploinsufficiency causes autistic-like behaviors linked to excessive synapses due to synapse pruning deficits. Mechanistically, deletion of Ash1l in neurons leads to downregulation of EphA7 through accumulation of EZH2-mediated H3K27me3 in the EphA7 gene body. Supplying ephrin-A5 (EphA7 ligand) in Ash1l+/- mice restores synapse pruning and rescues discrimination deficits.\",\n      \"method\": \"Conditional knockout mouse, ChIP (H3K27me3 at EphA7), ephrin-A5 rescue experiment, synapse quantification, behavioral assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP showing specific epigenetic mechanism at target gene, epistasis via EphA7/ephrin-A5 rescue, specific synaptic and behavioral phenotype\",\n      \"pmids\": [\"35081333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The ASH1L PHD finger non-selectively binds all three methylation states of H3K4 (me1, me2, me3) with comparable affinities. NMR structure of the PHD finger bound to H3K4me2 peptide shows a narrow binding groove restricting interaction with the dimethyl-ammonium moiety. The ASH1L PHD finger is identified as a native reader of methylated H3K4.\",\n      \"method\": \"NMR structure determination, peptide binding assays (ITC/NMR), site-directed mutagenesis\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with binding affinity measurements; single lab but rigorous structural and biochemical methods\",\n      \"pmids\": [\"36033518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The ASH1L-MRG15 complex deposits H3K4me3 genome-wide (outside active gene promoters) after UV irradiation, priming chromatin for XPC relocations. ASH1L-MRG15 also recruits the histone chaperone FACT to DNA lesions. Without ASH1L, MRG15 or FACT, XPC is misplaced and cannot deliver lesions to TFIIH for verification. Full-length MRG15 (but not MRG domain alone) enhances ASH1L activity by recruiting nucleosome substrate via MRG15 chromodomain.\",\n      \"method\": \"Co-IP, ChIP-seq, siRNA knockdown, NER activity assays, XPC relocalization imaging, in vitro methyltransferase assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, ChIP-seq, genetic knockdown with multiple pathway readouts; independent replication of ASH1L NER role (second paper from same group)\",\n      \"pmids\": [\"37393406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Full-length MRG15 (but not the MRG domain alone) enhances ASH1L catalytic activity by recruiting ASH1L to nucleosome substrate via the MRG15 chromodomain. MRG15 binding does not alter the conformation of the ASH1L SET domain autoinhibitory loop or the SAM cofactor binding site in solution, suggesting MRG15 functions as a substrate-recruiting adapter rather than an allosteric activator.\",\n      \"method\": \"In vitro methyltransferase assay, NMR, nucleosome binding assays, MRG domain vs full-length MRG15 comparison, small molecule inhibitor potency assay\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro assay with domain dissection, NMR for conformational analysis, contrasts with prior structural models; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"37527654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"METTL3 promotes ASH1L expression post-transcriptionally by enhancing ASH1L mRNA stability in a YTHDC2-dependent m6A reader mechanism. Elevated ASH1L in turn decreases IL-17 and IL-23R expression, reducing pathogenic Th17 responses.\",\n      \"method\": \"Overexpression/knockdown of METTL3, YTHDC2, and ASH1L; m6A mRNA stability assays; flow cytometry for Th17; in vivo EAU model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mRNA stability assay with YTHDC2 requirement established, functional Th17 readout, but no direct structural/enzymatic validation of ASH1L mechanism; single lab\",\n      \"pmids\": [\"36753389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Crystal structure and functional analysis of the ASH1L C-terminal region (bromodomain, PHD finger, and BAH domain) shows: ASH1LPHD recognizes H3K4me2/3; ASH1LBD and ASH1LBAH have DNA-binding activities; the ASH1LBAH domain's DNA-binding drives association with linker DNA in nucleosomes; the PHD-BAH interface stabilizes the BAH fold merging two domains into one module; and interaction of ASH1LPHD with H3K4me3 is inhibitory to the H3K36me2 catalytic activity of ASH1L.\",\n      \"method\": \"Crystal structure, in vitro binding assays, nucleosome interaction assays, methyltransferase activity assays with domain mutants, ChIP-seq in ESCs\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus in vitro binding/activity assays plus ChIP-seq in cells; multiple orthogonal methods establishing crosstalk mechanism\",\n      \"pmids\": [\"40044670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASH1L mediates H3K4me3 modification at the Stac2 promoter in osteoclast progenitors, increasing Stac2 transcription. STAC2 then protects against RANKL-initiated inflammation during osteoclast formation. Conditional deletion of Ash1l in osteoclast progenitors results in osteoporosis and enhanced osteoclastogenesis in vivo.\",\n      \"method\": \"Conditional knockout mouse (osteoclast progenitor-specific), ChIP (H3K4me3 at Stac2 promoter), osteoclast differentiation assay, bone histomorphometry\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockout with specific phenotype, ChIP establishing direct target gene regulation; single lab\",\n      \"pmids\": [\"38431690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Systematic perturbation of H3K36 methyltransferases demonstrates that ASH1L's H3K36me2 activity is restricted to regulatory elements of developmentally relevant genes. PBX2 is implicated as a potential ASH1L recruitment factor at these sites. ASH1L activity is positioned at the bottom of a hierarchy: NSD1 > NSD2 > NSD3 > ASH1L for H3K36me1/2 deposition.\",\n      \"method\": \"Sequential CRISPR knockouts of K36MTs in mouse mesenchymal stem cells, ChIP-seq, transcriptomics, motif analysis\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic genetic perturbation with genome-wide ChIP-seq; rigorous reductive approach establishing ASH1L-specific contribution\",\n      \"pmids\": [\"39390582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASH1L guards enhancer and promoter sequences against UV-induced cyclobutane pyrimidine dimer (CPD) formation at C-containing dinucleotides (but not TT dinucleotides or 6-4 photoproducts). This protective function is associated with H3K4me3 and H3K27ac histone marks that interact with ASH1L PHD and BRD motifs, respectively. Molecular dynamics simulations identified an AT hook in ASH1L that alters DNA geometry to disfavor pyrimidine dimerization.\",\n      \"method\": \"DNA damage mapping in ASH1L-proficient vs. deficient cells, molecular dynamics simulation, ChIP data correlation, mutation frequency analysis in skin cancers\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comparative DNA damage mapping in knockout cells plus MD simulation; single lab, novel mechanism (CPD prevention)\",\n      \"pmids\": [\"38884271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASH1L-mediated H3K4me3 modification increases CCL2 and CSF1 expression in hepatocytes and hepatic stellate cells, recruiting and polarizing M2-like pro-tumorigenic macrophages that enhance tumor proliferation and suppress CD8+ T cell activation in HCC. Conditional Ash1l deletion in hepatocytes or HSCs mitigates fibrosis and HCC development.\",\n      \"method\": \"Conditional knockout mice (Ash1lflox/flox Alb-Cre and GFAP-CreERT2), ChIP (H3K4me3 at CCL2/CSF1 promoters), single-cell RNA-seq, multicolor flow cytometry, AS-99 inhibitor treatment\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockouts with mechanistic ChIP data, single-cell transcriptomics, and pharmacological validation; single lab\",\n      \"pmids\": [\"39377228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The PHD-BAH domain of ASH1L preferentially binds H3K4me2 peptide over H3K4me1 and H3K4me3 in pull-down and ITC assays. The W2603A mutation in the PHD-BAH domain disrupts interaction with H3K4me2 in vitro. Deletion of the PHD-BAH domain in cholangiocarcinoma cells increases apoptosis and reduces proliferation, with dysregulation of the PSMB family gene set.\",\n      \"method\": \"Prokaryotic fusion protein pull-down, ITC, site-directed mutagenesis, CRISPR-Cas9 domain deletion, cell proliferation/apoptosis assays\",\n      \"journal\": \"Anti-cancer agents in medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ITC binding measurements plus mutagenesis plus functional cellular readout; single lab\",\n      \"pmids\": [\"39034728\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ASH1L is a Trithorax-group histone methyltransferase whose SET domain primarily catalyzes H3K36 mono- and dimethylation (and H3K4 methylation in certain contexts) on nucleosome substrates; its catalytic activity is normally autoinhibited by a post-SET loop that is relieved when MRG15 binds an FxLP motif N-terminal to the SET domain and recruits ASH1L to nucleosomes via MRG15's chromodomain. Additional C-terminal domains (PHD, BAH, bromodomain) bind H3K4me2/3 and linker DNA to stabilize chromatin association, while PHD–H3K4me3 interaction inhibits H3K36me2 catalytic activity, establishing intramolecular cross-regulation. At active genes, ASH1L-deposited H3K36me2 counteracts Polycomb silencing and is read by LEDGF to facilitate MLL complex recruitment; at DNA damage sites, DDB2-recruited ASH1L deposits H3K4me3 to enable XPC handoff and global-genome NER; in immune and neural contexts, ASH1L-mediated H3K4me3 at specific promoters activates A20/Tnfaip3, Smad3, Stac2, and synaptic genes to modulate inflammation, Treg differentiation, osteoclastogenesis, and neuronal activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ASH1L is a Trithorax-group SET-domain histone methyltransferase that deposits activating histone methylation at active genes and regulatory elements to counteract Polycomb silencing and sustain developmental gene expression programs [#4, #26]. Its catalytic SET domain mono- and dimethylates nucleosomal H3K36, requires intact native nucleosome substrate, and is intrinsically autoinhibited by a post-SET loop that occludes the substrate-binding pocket; mutation of this loop or a second SET-I loop relieves autoinhibition and modulates activity [#2, #5, #6]. Activation in cells is achieved when MRG15 binds an FxLP motif N-terminal to the SET domain and recruits ASH1L to nucleosomes via the MRG15 chromodomain, functioning principally as a substrate-recruiting adapter [#14, #22]. C-terminal PHD, BAH, and bromodomain modules read H3K4 methylation and bind linker DNA to stabilize chromatin engagement, and the PHD–H3K4me3 interaction feeds back to inhibit H3K36me2 catalysis, establishing intramolecular cross-regulation [#20, #24]. At active and leukemia-associated loci, ASH1L-written H3K36me2 is read by LEDGF to facilitate recruitment of wild-type and fusion MLL complexes, and ASH1L catalytic activity is required for MLL-rearranged leukemic transformation, making its autoinhibitory loop a validated drug target (AS-99) [#8, #17, #18]. ASH1L also deposits H3K4 methylation at specific promoters to control diverse physiological programs—enhancing the deubiquitinase A20/Tnfaip3 to restrain NF-κB-driven inflammation, Smad3 to promote Treg polarization, Stac2 in osteoclasts, and synaptic genes in neurons—and supports hematopoietic stem cell quiescence and myoblast fusion [#3, #11, #25, #16, #7, #12]. In genome maintenance, DDB2-recruited ASH1L, with MRG15 and FACT, methylates H3K4 at damaged nucleosomes to enable XPC handoff during global-genome nucleotide excision repair [#10, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the existence and domain architecture of human ASH1L as a multidomain chromatin protein, raising the question of where it acts in the cell.\",\n      \"evidence\": \"Immunofluorescence with multiple antibodies, co-labeling with junctional markers, and molecular cloning identifying SET, PHD, AT-hook, and bromodomain modules\",\n      \"pmids\": [\"10860993\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymatic activity not demonstrated\", \"Tight junction localization not mechanistically integrated with later nuclear chromatin functions\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"First showed ASH1L is a chromatin-associated methyltransferase at active genes, but assigned its SET domain to H3K4 methylation, leaving substrate specificity unsettled.\",\n      \"evidence\": \"Genome-wide ChIP, in vitro methyltransferase assay, siRNA knockdown with HoxA10 ChIP, and MLL-null cell lines\",\n      \"pmids\": [\"17923682\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"H3K4 vs H3K36 specificity conflicts with later biochemistry\", \"Recruitment mechanism to active genes undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the structural basis of catalysis and reassigned the primary substrate to H3K36, revealing post-SET autoinhibition as a built-in regulatory switch.\",\n      \"evidence\": \"X-ray crystallography of the catalytic domain, mutagenesis of the autoinhibitory loop, and in vitro methyltransferase assays\",\n      \"pmids\": [\"21239497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How autoinhibition is relieved physiologically not yet known\", \"Nucleosome substrate requirement not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected ASH1L SET activity to a Polycomb-antagonizing role in development and to direct promoter regulation of inflammatory genes, establishing functional readouts of its catalysis.\",\n      \"evidence\": \"Ash1l-knockout ES cells with DRB treatment and ChIP-seq (H3K36me2 at Hox loci); ChIP, SET-mutant rescue, and Co-IP at the Tnfaip3/A20 promoter in macrophages\",\n      \"pmids\": [\"24244179\", \"24012418\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Recruitment factors directing ASH1L to specific loci not identified\", \"Distinction between transcription-coupled and uncoupled methylation incomplete\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established that robust ASH1L activity depends on native nucleosome substrate and on coordinated SET-domain loop dynamics plus C-terminal chromatin-reader domains, refining the catalytic mechanism.\",\n      \"evidence\": \"NMR, X-ray crystallography, mutagenesis, and kinetic methyltransferase assays with recombinant nucleosomes and H3K36A substrate mutants\",\n      \"pmids\": [\"26292256\", \"26002201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological activator of autoinhibition still unidentified\", \"C-terminal domain contributions to chromatin targeting not structurally resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined ASH1L as a regulator of adult stem cell quiescence and self-renewal acting in genetic parallel with MLL1.\",\n      \"evidence\": \"Conditional knockout mice, bone marrow transplantation, cell-cycle analysis, and Ash1l/Mll1 double-mutant epistasis\",\n      \"pmids\": [\"25866973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes mediating quiescence beyond Hox/Cdkn1b not fully mapped\", \"Catalytic dependence of HSC phenotype not isolated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified LEDGF as a reader of ASH1L-deposited H3K36me2 that bridges to MLL complex recruitment, defining how this mark sustains MLL-dependent leukemia.\",\n      \"evidence\": \"Reciprocal ChIP-seq co-localization, Co-IP, leukemia transformation assays, and KDM2A antagonism\",\n      \"pmids\": [\"27154821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ASH1L catalytic activity (vs scaffolding) drives transformation not resolved here\", \"Direct ASH1L–LEDGF vs mark-mediated recruitment not distinguished\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended ASH1L function to activity-dependent neuronal gene regulation, showing it can mediate transcriptional repression via promoter H3K36me2.\",\n      \"evidence\": \"Promoter pulldown, ChIP, Ash1l-knockout mice, and electrophysiological stimulation of cortical neurons\",\n      \"pmids\": [\"27229316\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which H3K36me2 represses nrxn1α not defined\", \"Single-locus focus limits generality\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a chromatin-priming role in DNA repair, with DDB2-recruited ASH1L methylating H3K4 to enable XPC handoff in global-genome NER.\",\n      \"evidence\": \"Co-IP, ChIP, siRNA knockdown, UV survival, CPD excision assays, and co-localization imaging\",\n      \"pmids\": [\"29109511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"H3K4 (vs H3K36) specificity at lesions contrasts with bulk biochemistry\", \"Direct vs indirect ASH1L–XPC interplay not fully separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed ASH1L directly activates Smad3 transcription via promoter H3K4me3 to drive Treg polarization, with a lncRNA/HDAC1 axis competing for promoter access.\",\n      \"evidence\": \"ChIP, knockdown, Co-IP at the Smad3 promoter, lnc-Smad3/HDAC1 interaction assays, and in vitro Treg polarization\",\n      \"pmids\": [\"28598443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TGF-β signaling spatially coordinates ASH1L recruitment unresolved\", \"Generalizability beyond Smad3 locus untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Confirmed ASH1L as a Polycomb-counteracting activator in differentiation by enabling myoblast fusion and mesenchymal lineage decisions through SET-dependent promoter activation.\",\n      \"evidence\": \"RNA-seq, ChIP-seq, multi-system loss-of-function, SET-domain fragment overexpression/rescue, and in vivo transplantation\",\n      \"pmids\": [\"30487570\", \"30270478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Recruitment to lineage-specific promoters not mechanistically defined\", \"Direct vs secondary effects on differentiation factors not fully separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Solved how ASH1L is physiologically activated, showing MRG15 binds an FxLP motif N-terminal to the SET domain to relieve post-SET autoinhibition.\",\n      \"evidence\": \"Independent crystal structures of ASH1L–MRG15 from two groups with methyltransferase assays and mutagenesis\",\n      \"pmids\": [\"30827841\", \"30827843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MRG15 acts allosterically or as a substrate adapter left ambiguous\", \"In vivo requirement of MRG15 for ASH1L targeting not established here\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that ASH1L catalytic activity is required for MLL-rearranged leukemia and that its autoinhibitory loop is a druggable pocket.\",\n      \"evidence\": \"Catalytic-dead vs WT rescue in conditional knockout leukemia models with ChIP-seq; fragment-based discovery of AS-99 with inhibitor co-crystal structures and in vivo efficacy\",\n      \"pmids\": [\"34692539\", \"33990599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity of AS-99 against other K36 methyltransferases not detailed here\", \"Scaffolding-independent catalytic requirement at all target genes not exhaustively mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked ASH1L to neurodevelopmental disease by showing its H3K4me3 deposition at synaptic genes maintains excitatory/inhibitory balance.\",\n      \"evidence\": \"Viral shRNA knockdown in prefrontal cortex, H3K4me3 ChIP-seq, patch-clamp electrophysiology, chemogenetic and pharmacological rescue\",\n      \"pmids\": [\"34782621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ASH1L promoter binding vs indirect effects not separated for all synaptic genes\", \"Relationship to its H3K36me2 activity in neurons unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the ASH1L PHD finger as a reader of methylated H3K4 and uncovered a haploinsufficiency mechanism for autism via Polycomb-mediated EphA7 silencing.\",\n      \"evidence\": \"NMR structure and binding assays of the PHD finger; conditional knockout, H3K27me3 ChIP at EphA7, and ephrin-A5 rescue with behavioral readouts\",\n      \"pmids\": [\"36033518\", \"35081333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PHD H3K4me reading is coupled to catalysis not yet integrated\", \"Direct vs indirect control of EZH2 activity at EphA7 unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved the role of MRG15 as a substrate-recruiting adapter via its chromodomain and extended the ASH1L–MRG15 module to FACT recruitment in NER.\",\n      \"evidence\": \"Co-IP, ChIP-seq, NER assays, XPC imaging, and in vitro methyltransferase assays comparing full-length MRG15 vs MRG domain alone\",\n      \"pmids\": [\"37393406\", \"37527654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation of adapter vs allosteric models across studies incomplete\", \"In vivo stoichiometry of the ASH1L–MRG15–FACT module unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Placed ASH1L downstream of m6A regulation, showing METTL3/YTHDC2 stabilize ASH1L mRNA to dampen pathogenic Th17 responses.\",\n      \"evidence\": \"Overexpression/knockdown of METTL3, YTHDC2 and ASH1L, m6A mRNA stability assays, Th17 flow cytometry, and an in vivo EAU model\",\n      \"pmids\": [\"36753389\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural/enzymatic validation of ASH1L action on IL-17/IL-23R\", \"Direct ASH1L target promoters in Th17 not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined the integrated C-terminal reader module (PHD-BAH-bromodomain) and its DNA/H3K4me binding, revealing PHD–H3K4me3-dependent inhibition of catalysis as intramolecular cross-regulation.\",\n      \"evidence\": \"Crystal structure, in vitro binding and nucleosome assays, domain-mutant methyltransferase assays, ITC, and ChIP-seq in ESCs and cancer cells\",\n      \"pmids\": [\"40044670\", \"39034728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How reader-mediated feedback is regulated in vivo unknown\", \"Conflicting H3K4 methyl-state preferences across PHD vs PHD-BAH constructs\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Quantified ASH1L's restricted, hierarchical contribution to H3K36me2 at developmental regulatory elements and nominated PBX2 as a recruitment factor.\",\n      \"evidence\": \"Sequential CRISPR knockouts of K36 methyltransferases in mesenchymal stem cells with ChIP-seq, transcriptomics, and motif analysis\",\n      \"pmids\": [\"39390582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PBX2–ASH1L interaction not biochemically validated\", \"Mechanism setting the NSD>ASH1L hierarchy unexplained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended ASH1L H3K4me3 promoter activation to additional disease-relevant programs and uncovered a non-catalytic DNA-protective function against UV damage.\",\n      \"evidence\": \"Osteoclast- and hepatocyte/HSC-specific conditional knockouts with ChIP at Stac2/CCL2/CSF1 promoters and AS-99 treatment; DNA damage mapping plus molecular dynamics of an AT hook in ASH1L-deficient cells\",\n      \"pmids\": [\"38431690\", \"39377228\", \"38884271\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"AT-hook-mediated CPD prevention is a single-lab novel mechanism awaiting independent confirmation\", \"Catalytic vs structural contributions to the protective role not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ASH1L's locus-specific recruitment, the catalytic switch between H3K36me2 and context-dependent H3K4 methylation, and reader-mediated feedback are integrated into a unified targeting logic in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model reconciling H3K36me2 vs H3K4 methylation outputs across contexts\", \"Sequence-specific recruitment factors largely unvalidated biochemically\", \"In vivo interplay of autoinhibition, MRG15 activation, and PHD feedback not measured\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 6, 14]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 6, 24]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [20, 24, 29]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [24, 27]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 4, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [1, 4, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 24, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 3, 11]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [10, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 12, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 11, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 17, 18, 28]}\n    ],\n    \"complexes\": [\"ASH1L-MRG15 complex\"],\n    \"partners\": [\"MRG15\", \"LEDGF\", \"DDB2\", \"XPC\", \"FACT\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}